Tonix Pharmaceuticals Expands Prπ'☆φeclinical Pipeline witπ♦h Triple Reuptake Inhibitor, TNX-1600, for the Treatme☆✘nt of PTSD
Tonix Pharmaceutical®↑s Holding Corp., a cliβnical-stage biopharmace£$σ£utical company, announced today an exclusive ↑€&₩agreement to in-license a triple reupta ∑ke inhibitor (TRI), TNX-1600 (forme₩σ£&rly D-578), to treat posttraumatic stress≠β¶ disorder (PTSD) and potentially othe&πr central nervous system (CNS) disord✘'→ers. The compound waΩ₹s developed and pharmacol∏✔ogically characterized by Aloke Dutta, Ph.D., ÷<professor of Pharmaceutical Sciences∑₹Ω at Wayne State University, with funding from aγ↓π€ National Institutes of Health grant (g₩÷€ rant number MH084888), and the patents cover↔¶ing the compounds were licensed to TRImaran Phar ✔ma, Inc. (TRImaran).¥₽φ The transaction announced today is a l §icense agreement wit×±β÷h Wayne State and an as♥ ♣set acquisition with TRImaλ∞↓ran.“We are excited tπ✔→©o expand our pipeline and are Ω₽looking forward to developing§"₩∞ TNX-1600 as a potential treatm✘λ®φent for PTSD,” said Seth Lederman, M♣"↔.D., Tonix's President and Chπ¶ ←ief Executive Officer. “We pla₩αn to utilize our clinic✔•α&al experience in PTSD to ★πevaluate the therapeuti✔£✔c benefit of TNX-1600. PTSD is a heterogeneous c>ondition, so we believe different PTSD 'φpatients may respond to different m→•→edicines. In some cases, more than o♣♦♣ne drug will be required for effective trea ↓φσtment. TNX-1600 is our third drug candidate£Ω × in development for PTSD. Our most advanced can$↓ didate is TNX-102 SL, whic↔<©¥h is in Phase 3 development. We are also dφ∑eveloping TNX-601 which is enteringΩφ a Phase 1 trial imminently. TNX∏&α×-1600 is in the pre-IND phase of✔" development with encouraging data from a$♦α₹nimal models of PTSD.”Frank ÷δ" Bymaster, Chief Scientific Oδ✘★δfficer and co-founder of TRImaran Pharma Inc. sai≠•d, “TNX-1600 is a novel TRI that inhibits simulta>& neously the reuptake of threeπε&Ω key neurotransmitters: serotonin, nor™>epinephrine and dopamine. Each of these th×→ree neurotransmitters plays a key modulatλ•ory role in many CNS processes. Inhibiσ≥↔ting reuptake of all three ∏≥♥may provide an effective treatment for PTSD.”Accα•♦♣ording to Dr. Aloke Dutta, “We have dev>₹↔×eloped an innovative triple reuptake in§£≥♠hibitor, D-578, based on a unique pyran molec★∑Ωular scaffold to address the cu"™rrent therapeutic needs >λ§ for PTSD and other ne↕↓urological disorders.γλ Based on our preliminary data, we expect a phar→♥₩macological synergy from theββ''ir potent modulatory effect on $πthe level of monoamine neurotransmitters in the₹✔• brain which should facilitate effectiv≠ε€e treatment of these disorders.”Under th↓ e terms of the agreement, Tonixφ'±♦ has been granted an exclusive l✔πicense from Wayne Sta$α'te University for technology and patents£÷£φ related to TNX-1600 and other pyran-bas×←ed compounds. Another member ™ '→of the class, D-473, has also sho≤↔wn effects in a rodent model&✘π of depression.the 2019 Asia-pacif≤" αic Pharmaceutical IP Leader S₽'←$ummit will be held in Beijing on November 1£β4-15, and will attract more than 50÷®0 industry experts from domeπ ∏₩stic and foreign pharmaceutical companies, bε§iotechnology companies, governments, asso↓Ω¶ciations, law firms, inte ✘llectual property agents and other companies to aβ™÷$ttend. 2019 Asia-pacific Pharmaceu§♣ε•tical IP Leader Summit Official≤ ββ registration and consultation channels:Contac$≤☆↑t:AnnPhone: 021-65650305Email:Marketing@zenseegφ§± roup.comhttp://en.zenseegroup.com/p/•∑™510934/